تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Merck & Co., Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $370.9B | |
|---|---|---|
| Revenue (ttm) | 66.6B | |
| Net income (ttm) | 3.2B | |
| EPS (ttm) | $1.27 | |
| Shares out | 2.5B | |
| P/E (trailing) | 110.8x | |
| P/E (forward) | 15.7x | |
| Dividend | $3.40 (2.42%) | |
| Volume | 6,404,220 | |
| Beta | 0.22 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $48.70B | $59.28B | $60.12B | $64.17B | $65.01B | +7.5% |
| Gross profit | $35.08B | $41.87B | $43.99B | $48.98B | $46.73B | +7.4% |
| Operating income | $14.69B | $17.41B | $3.04B | $21.21B | $22.42B | +11.2% |
| Net income | $13.05B | $14.52B | $365.0M | $17.12B | $18.25B | +8.8% |
| EPS (diluted) | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 | +9.1% |
| EBITDA | $17.90B | $21.32B | $6.91B | $25.71B | $28.26B | +12.1% |
| R&D | $12.25B | $13.55B | $30.53B | $17.94B | $15.79B | +6.6% |
| SG&A | $9.63B | $10.04B | $10.50B | $10.82B | $10.73B | +2.7% |
Recent company headlines from major financial publishers.
Revenue recovery continues, margins normalize and per-share results receive modest support from a lower share count. Later growth remains measured rather than accelerating.
Upside persists if growth and margins last beyond the rebound. It fades if stronger results require more investment or debt than operating cash can fund.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 4.6% | $176 | $195 | $223 | $268 | $352 |
| 5.6% | $146 | $156 | $169 | $187 | $214 |
| 6.6% | $127 | $133 | $141 | $150 | $163 |
| 7.6% | $114 | $118 | $122 | $128 | $135 |
| 8.6% | $104 | $107 | $110 | $114 | $118 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
